As part of the synergy, the companies will launch hybrid business model.
Ranbaxy will support Daiichi Sankyo Brasil Farmaceutica, Daiichi Sankyo’s Brazilian subsidiary, to enter into branded generics market along with the innovative product business.
Through its hybrid business model, Daiichi will promote innovative, branded generic and generic pharmaceuticals and expand business in Brazil.
Ranbaxy Farmaceutica, the Brazilian subsidiary of Ranbaxy, continues to separately promote its generic products and additionally enter branded generics in the region.